Findme Specialist Doctors

Profile

Dr. 鈴木 育宏

所属病院

東海大学医学部付属八王子病院
乳腺・内分泌外科教授、オンコロジーセンター長

Locations
東京都八王子市石川町1838
Phone
042-639-1111
Dr. 鈴木 育宏に治療相談を申し込む
Findmeスペシャリストドクターズは専門医にオンラインで治療の相談を受けることができるサービスです。30分 25,800円から。ご利用には会員登録が必要です。
  • Customer's Voice利用者の声

    分かりやすく説明して頂いて、モヤモヤしていたものがスッキリしました。とても話しやすく、簡単に説明してくださったので理解しやすかったです!ありがとうございました!

    鈴木 育宏先生へのお礼や感謝の気持ちを絶賛大募集いたします。

  • About me私について

    大学病院を中心として、乳腺外科一筋に約25年を乳がん患者さまとその家族の為に過ごしてきました。たくさんの方に出会い、教科書には書いていないことをたくさん教えてもらいました。今までどおり、患者ファーストの姿勢で進んで参ります。少しでも皆さまのお力になれ、道に迷わないようにサポート致します。見た目より優しいので(笑)お気軽にアクセスして下さい。

    私がライフワークとして取り組んでいる「再発乳癌の薬物療法」ですが、何種類もある薬剤から、患者さまの病状、気持ち、環境など、様々なことを組み込んで最適な治療法を一緒に考えます。
    治療法の正解は、その人、その人で全く違います。
    その方にとって、正解になりますよう、お手伝いをしますので、ぜひ声をお聞かせ下さい。

  • Career経歴

    1990年3月 東海大学医学部医学科卒業
    1990年6月 東海大学医学部付属病院前期研修医
    1992年5月 国立東静病院(現国立病院機構 静岡医療センター)
    1997年4月 東海大学医学部付属大磯病院
    1998年4月 恩賜財団済生会平塚病院
    2010年4月 東海大学医学部乳腺・内分泌外科准教授
    2012年4月 東海大学医学部付属八王子病院 オンコロジーセンター長
    2015年10月 東海大学医学部付属病院
    2018年4月 東海大学医学部乳腺・内分泌外科教授 付属八王子病院勤務 オンコロジーセンター長
  • Affiliation所属学会

    日本外科学会(専門医、指導医)

    日本乳癌学会(専門医、指導医、評議員)

    日本臨床外科学会(評議員)

    日本リンパ浮腫治療学会(評議員)

    日本臨床腫瘍学会

    日本癌治療学会

    日本癌学会

    日本緩和医療学会

    日本がん治療認定医機構がん治療認定医

  • Specialized field / Recommendation専門分野 / 推薦

    □乳腺外科

    □乳がん薬物療法

    □乳がんの縮小手術

  • Qualification · Awards history資格・受賞歴

    日本外科学会(専門医、指導医)

    日本乳癌学会(専門医、指導医)

    日本がん治療認定医機構がん治療認定医

  • Medical society papers ・ Presentation history論文・発表歴

    • Narui K. Ishikawa T. Shimizu D. Yamada A. Tanabe M. Sasaki T. Oba MS. Morita S. Nawata S. Kida K. Mogaki M. Doi T. Tsugawa K. Ogata H. Ota T. Kosaka Y. Sengoku N. Kuranami M. Niikura N. Saito Y. Suzuki Y. Suto A. Arioka H. Chishima T. Ichikawa Y. Endo I. Tokuda Y.

      Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.

    • Tsuda B. Kumaki N. Ishida R. Mizuno M. Yokoyama K. Oshitanai R. Terao M. Morioka T. Okamura T. Saito Y. Suzuki Y. Niikura N.

      Distinction of IgG4-related mastitis from breast cancer: a case report.

    • Morioka T. Niikura N. Kumaki N. Masuda S. Iwamoto T. Yokoyama K. Ogiya R. Oshitanai R. Terao M. Tsuda B. Okamura T. Saito Y. Suzuki.Y, Tokuda.Y.

      Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists.

    • Tsuda B. Yokoyama K. Ogiya R. Miyamoto A. Oshitanai R. Terao M. Morioka T. Niikura N. Okamura T. Miyako H. Saito Y. Suzuki Y. Kametani Y. Tokuda Y.

      B-cell populations are expanded in breast cancer patients compared with healthy controls.

    • Terao M. Niikura N. Suzuki Y. Tokuda Y. Sengoku N. Arioka H. Ishikawa T.

      Management of Breast Cancer in Adjuvant Chemotherapy Settings in the Kanagawa Breast Oncology Group.

    • Suzuki.Y, Yokoyama.K, Terao.M, Morioka.T, Tsuda.B, Niikura.N, Okamura.T, Yamada.E, Imagawa.K, Akamatsu.T, Tokuda.Y, Kumaki.N.

      Pyoderma gangrenosum after breast mastectomy and primary rectus abdominis flap reconstruction.

    • Ogiya.R, Niikura.N, Kumaki.N, Bianchini G, Kitano.S, Iwamoto.T, Hayashi.N, Yokoyama.K, Oshitanai.R, Terao.M, Morioka.T, Tsuda.B, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.

    • Saito.Y, Suzuk. Y, Inomoto.C, Kumaki.N, Yokoyama.K, Ogiya.R, Oshitanai.R, Terao.M, Tsuda.B, Morioka.T, Niikura.N, Okamura.T, Masuda.S, Tokuda.Y.

      A case of giant borderline phyllodes tumor of the breast associated with hypoglycemia.

    • Mokuyasu.S, Suzuki.Y, Kawahara.E, Seto.T, Tokuda.Y.

      High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer.

    • Tsuda.B, Kametani.Y, Miyamoto.A, Miyako.H, Kumaki.N, Ogiya.R, Oshitanai.R, Terao.M, Morioka.T, Niikura.N, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      The effect of peptide treatment on the HLA-binding and antibody production in peripheral blood mononuclear cells obtained from japanese breast cancer patients.

    • Terada.M, Niikura.N, Tsuda.B, Masuda.S, Kumaki.N, Tang X, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Comparative study of the one-step nucleic acid amplification assay and conventional histological examination for the detection of breast cancer sentinel lymph node metastases.

    • Suzuki.Y, Ogiya.R, Oshitanai.R, Terao.M, Terada.M, Morioka.T, Tsuda.B, Niikura.N, Okamura.T, Saito.Y, Tokuda.Y.

      Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.

    • Niikura.N, Masuda.S, Kumaki.N, Tang X, Terada.M, Terao.M, Iwamoto.T, Oshitanai.R, Morioka.T, Tuda.B, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.

    • Tang X, Umemura.S, Kumaki.N, Izumi.M, Saito.Y, Suzuki.Y, Ozawa.A, Tokuda.Y.

      A case report of pigmented mammary Paget's disease mimicking nevus of the nipple.

    • Okamura.T, Tang X, Saito.Y, Suzuki.Y, Masuda.S, Tokuda.Y.

      Pleomorphic lobular carcinoma with lipid-producing activity: a report of 2 cases.

    • Suzuki.Y, Saeki.T, Aogi.K, Toi.M, Fujii.H, Inoue.K, Watanabe.T, Fujiwara.Y, Ito.Y, Takatsuka.Y, Iwata.H, Arioka.H, Tokuda.Y.

      A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.

    • Niikura.N, Kimura.M, Iwamoto.T, Hayashi.N, Shintoku.J, Saito.Y, Suzuki.Y, Tokuda.Y.

      Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.

    • Tsuda.B, Kametani.Y, Goto.Y, Saito.Y, Suzuki.Y, Habu.S, Inoko.H, Tokuda.Y.

      A human B cell receptor epitope-based erbB-2 peptide (N: 163-182) with pan-reactivity to the T cells of japanese breast cancer patients.

    • Niikura.N, Iwamoto.T, Masuda.S, Kumaki.N, Tang X, Shirane.M, Mori.K, Tsuda.B, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Immunohistochemical Ki67 labeling index has a similar proliferation predictive power as various gene signatures breast cancer.

    • Mokuyasu.S, Suzuki.Y, Seto.T, Miyachi.H, Tokuda.Y.

      A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.

    • Saito.Y, Oshitanai.R, Terao.M, Terada.M, Tsuda.B, Okamura.T, Suzuki.Y, Tokuda.Y.

      Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.

    • Kumaki.M, Umemura.S, Tang.X, Saito.Y, Suzuki.Y, Tokuda.Y.

      Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.

    • Suzuki.Y, Saito.Y, Terao.M, Terada.M, Morioka.T, Tsuda.B, Okamura.T, Niikura.N, Tokuda.Y.

      Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.

    • Niikura.N, Kimura.M, Hirabayashi.K, Umemura.S, Minakawa.T, Shintoku.J, Suzuki.Y, Tokuda.Y.

      Breast conserving surgery for male noninvasive intracystic papillary carcinoma: a case report.

    • Saito.Y, Suzuki.Y, Tokuda.Y.

      Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.

    • Suzuki.Y, Tokuda.Y, Fujiwara.Y, Iwata.H, Sasaki.Y, Saji.S, Aogi.K, Nambu.Y, Suri A. Saeki.T, Takashima.S.

      Phase II study of gemcitabine monotherapy as salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.

    • Tokuda.Y, Suzuki.Y, Saito.Y, Umemura.S.

      The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.

    • Suzuki.Y, Tokuda.Y, Fujiwara.Y, Minami.H, Ohashi.Y, Saijo.N.

      Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.

    • Sato.H, Suzuki.Y, Fukasawa.M, Yasuda.M, Osamura.RY.

      De novo multiple endocrine neoplasia type 2B with noncardiogenic pulmonary edema as the presenting symptom.

    • Okada.K, Suzuki.Y, Saito.Y, Umemura.S, Tokuda.Y.

      Two cases of ductal adenoma of the breast.

    • Umemura.S, Takekoshi.S, Suzuki.Y, Saitoh.Y, Tokuda.Y, Osamura.RY.

      Estrogen receptor-negative and human epidermal growth factor receptor-2 negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.

    • Suzuki.Y, Tokuda.Y, Saito.Y, Umemura.S, Osamura.RY.

      Clinicopathological correlation between expression of PTHrP receptor and various prognostic factors in breast cancer without axillary lymph node metastasis.

    • Umemura.S, Itoh.J, Itoh.H, Serizawa.A, Saito.Y, Suzuki.Y, Tokuda.T, Tajima.T, Osamura.RY.

      Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?

    • Suzuki.Y, Tokuda.Y, Saito.Y, Ohta.M, Tajima.T.

      Combination of trastuzumab and vinorelbine in metastatic breast cancer.

    • Sekido.Y, Umemura.S, Takekoshi.S, Suzuki.Y, Tokuda.Y, Tajima.T, Osamura.RY.

      Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.

    • Umemura.S, Itoh.H, Ohta.M, Suzuki.Y, Kubota.M, Tokuda.Y, Tajima.T, Osamura.RY.

      Immunohistochemical evaluation of hormone receptor for routine practice of breast cancer: highly sensitive procedures significantly contribute to the correlation with biochemical assays.

    • Ohta.M, Tokuda.Y, Suzuki.Y, Kubota.M, Watanabe.T, Fujii.H, Sasaki.Y, Niwa.T, Makuuchi.H, Tajima.T.

      A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.

    • Tokuda.Y, Suzuki.Y, Ohta.M, Saito.Y, Kubota.M, Tajima.T, Umemura.S, Osamura.RY.

      Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan.

    • Tokuda.Y, Ohta.M, Suzuki.Y, Kubota.M, Tajima.T.

      Clinical development of trastuzumab in breast cancer.

    • Ohta.M, Tokuda.Y, Suzuki.Y, Kubota.M, Makuuchi.H, Tajima.T, Nasu.S, Suzuki.Y, Yasuda.S, Shohtsu.A.

      The whole-body PET for evaluation of bony metastases in the patients with breast cancer: comparison with Tc-99m MDP bone scintigraphy.

    • Suzuki.Y, Tokuda.Y, Okumura.A, Saito.Y, Ohta.M, Kubota.M, Makuuchi.H, Tajima.T, Umemura.S, Osamura.RY.

      Three cases of malignant lymphoma of the breast.

    • Ohta.M, Tokuda.Y, Saitoh.Y, Suzuki.Y, Okumura.A, Kubota.M, Makuuchi.H, Tajima.T, Yasuda.S, Shohtsu.A.

      Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer.

    • Okumura.A, Tokuda.Y, Ohta.M, Suzuki.Y, Saito.Y, Kuge.S, Makuuchi.H, Tajima.T, Nakamura.Y, Hotta.T.

      Autografting with peripheral blood CD34-positive cells following high-dose chemotherapy against breast cancer.

    • Ohta.M, Tokuda.Y, Kameya.T, Suzuki.Y, Kuge.S, Okumura.A, Kubota.M, Makuuchi.H, Tajima.T, Shimamura.K, Uchida.S, Mitsunaga.S, Tadokoro.K, Juji.T.

      GVHD after intraoperative blood transfusion: A rare and lethal condition.

    • Tajima.T, Kuge.S, Suzuki.Y, Okumura.A, Ohta.M, Tokuda.Y, Kubota.M.

      Dose-intensified chemotherapy for breast cancer: present and future prospects.

    • Yasuda.S, Shohtsu.A, Ide.M, Takagi.S, Suzuki.Y, Tajima.T.

      Diffuse F-18 FDG uptake in chronic thyroiditis.

    • Ohta.M, Tokuda.Y, Suzuki.Y, Kuge.S, Okumura.A, Kubota.M, Tajima.T, R. Osamura.RY, Mitomi.T.

      A case of multiple endocrine neoplasia type 2B.

    • 術前検査で乳癌を強く疑った線維腺腫の1例

      日本乳癌検診学会誌2012;21:78-81

    • 乳腺紡錐細胞癌の1例

      乳癌の臨床. 2008;23:135-139

    • 乳癌脳転移症例の臨床病理学的検討

      乳癌の臨床. 2004;19:606-607

    • 超音波検査にて乳腺浸潤が疑われた急性リンパ性白血病の1例.

      Journal of medical Ultrasonics 2000;27:805-810

    • 乳癌術後放射線照射後に発生したmalignant fibrous histiocytomaの1例

      日本臨床外科学会雑誌1996;57(12):2942-2946

    • 粘膜下腫瘍の形態を示し術前に確診が得られなかった高分化型早期胃癌の1例

      胃と腸. 1995;33(6):827-832

Dr. 鈴木 育宏に治療相談を申し込む
TOP > 詳細プロフィール:Dr. 鈴木 育宏
詳細プロフィール:Dr. 鈴木 育宏
Profile

Dr. 鈴木 育宏

東海大学医学部付属八王子病院
乳腺・内分泌外科教授、オンコロジーセンター長

所在地
東京都八王子市石川町1838
電話番号
042-639-1111
Dr. 鈴木 育宏に治療相談を申し込む
お問い合わせフォーム
  • 自己紹介Self-introduction

    大学病院を中心として、乳腺外科一筋に約25年を乳がん患者さまとその家族の為に過ごしてきました。たくさんの方に出会い、教科書には書いていないことをたくさん教えてもらいました。今までどおり、患者ファーストの姿勢で進んで参ります。少しでも皆さまのお力になれ、道に迷わないようにサポート致します。見た目より優しいので(笑)お気軽にアクセスして下さい。

    私がライフワークとして取り組んでいる「再発乳癌の薬物療法」ですが、何種類もある薬剤から、患者さまの病状、気持ち、環境など、様々なことを組み込んで最適な治療法を一緒に考えます。
    治療法の正解は、その人、その人で全く違います。
    その方にとって、正解になりますよう、お手伝いをしますので、ぜひ声をお聞かせ下さい。

  • 利用者の声Customer's Voice

    女性
    分かりやすく説明して頂いて、モヤモヤしていたものがスッキリしました。とても話しやすく、簡単に説明してくださったので理解しやすかったです!ありがとうございました!
    乳がん 30代 女性

    鈴木 育宏先生へのお礼や感謝の気持ちを絶賛大募集いたします。

  • 予約可能なスケジュールReservable schedule

    平日:18時以降、第2、4土曜日:相談可
  • よくあるご相談FAQ

    再発時の化学療法の選択について教えてください

    乳房を温存できますか、それとも全摘ですか

  • 経歴Career

    1990年3月
    東海大学医学部医学科卒業
    1990年6月
    東海大学医学部付属病院前期研修医
    1992年5月
    国立東静病院(現国立病院機構 静岡医療センター)
    1997年4月
    東海大学医学部付属大磯病院
    1998年4月
    恩賜財団済生会平塚病院
    2010年4月
    東海大学医学部乳腺・内分泌外科准教授
    2012年4月
    東海大学医学部付属八王子病院 オンコロジーセンター長
    2015年10月
    東海大学医学部付属病院
    2018年4月
    東海大学医学部乳腺・内分泌外科教授 付属八王子病院勤務 オンコロジーセンター長
  • 専門分野・得意治療法Specialized field ・ Specialized treatment

    専門分野

    □ 乳腺外科

    □ 乳がん薬物療法

    □ 乳がんの縮小手術

  • 資格・受賞歴Qualification · Awards history

    日本外科学会(専門医、指導医)

    日本乳癌学会(専門医、指導医)

    日本がん治療認定医機構がん治療認定医

  • 論文・発表歴Medical society papers ・ Presentation history

    • Narui K. Ishikawa T. Shimizu D. Yamada A. Tanabe M. Sasaki T. Oba MS. Morita S. Nawata S. Kida K. Mogaki M. Doi T. Tsugawa K. Ogata H. Ota T. Kosaka Y. Sengoku N. Kuranami M. Niikura N. Saito Y. Suzuki Y. Suto A. Arioka H. Chishima T. Ichikawa Y. Endo I. Tokuda Y.

      Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.

    • Tsuda B. Kumaki N. Ishida R. Mizuno M. Yokoyama K. Oshitanai R. Terao M. Morioka T. Okamura T. Saito Y. Suzuki Y. Niikura N.

      Distinction of IgG4-related mastitis from breast cancer: a case report.

    • Morioka T. Niikura N. Kumaki N. Masuda S. Iwamoto T. Yokoyama K. Ogiya R. Oshitanai R. Terao M. Tsuda B. Okamura T. Saito Y. Suzuki.Y, Tokuda.Y.

      Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists.

    • Tsuda B. Yokoyama K. Ogiya R. Miyamoto A. Oshitanai R. Terao M. Morioka T. Niikura N. Okamura T. Miyako H. Saito Y. Suzuki Y. Kametani Y. Tokuda Y.

      B-cell populations are expanded in breast cancer patients compared with healthy controls.

    • Terao M. Niikura N. Suzuki Y. Tokuda Y. Sengoku N. Arioka H. Ishikawa T.

      Management of Breast Cancer in Adjuvant Chemotherapy Settings in the Kanagawa Breast Oncology Group.

    • Suzuki.Y, Yokoyama.K, Terao.M, Morioka.T, Tsuda.B, Niikura.N, Okamura.T, Yamada.E, Imagawa.K, Akamatsu.T, Tokuda.Y, Kumaki.N.

      Pyoderma gangrenosum after breast mastectomy and primary rectus abdominis flap reconstruction.

    • Ogiya.R, Niikura.N, Kumaki.N, Bianchini G, Kitano.S, Iwamoto.T, Hayashi.N, Yokoyama.K, Oshitanai.R, Terao.M, Morioka.T, Tsuda.B, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.

    • Saito.Y, Suzuk. Y, Inomoto.C, Kumaki.N, Yokoyama.K, Ogiya.R, Oshitanai.R, Terao.M, Tsuda.B, Morioka.T, Niikura.N, Okamura.T, Masuda.S, Tokuda.Y.

      A case of giant borderline phyllodes tumor of the breast associated with hypoglycemia.

    • Mokuyasu.S, Suzuki.Y, Kawahara.E, Seto.T, Tokuda.Y.

      High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer.

    • Tsuda.B, Kametani.Y, Miyamoto.A, Miyako.H, Kumaki.N, Ogiya.R, Oshitanai.R, Terao.M, Morioka.T, Niikura.N, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      The effect of peptide treatment on the HLA-binding and antibody production in peripheral blood mononuclear cells obtained from japanese breast cancer patients.

    • Terada.M, Niikura.N, Tsuda.B, Masuda.S, Kumaki.N, Tang X, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Comparative study of the one-step nucleic acid amplification assay and conventional histological examination for the detection of breast cancer sentinel lymph node metastases.

    • Suzuki.Y, Ogiya.R, Oshitanai.R, Terao.M, Terada.M, Morioka.T, Tsuda.B, Niikura.N, Okamura.T, Saito.Y, Tokuda.Y.

      Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.

    • Niikura.N, Masuda.S, Kumaki.N, Tang X, Terada.M, Terao.M, Iwamoto.T, Oshitanai.R, Morioka.T, Tuda.B, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.

    • Tang X, Umemura.S, Kumaki.N, Izumi.M, Saito.Y, Suzuki.Y, Ozawa.A, Tokuda.Y.

      A case report of pigmented mammary Paget's disease mimicking nevus of the nipple.

    • Okamura.T, Tang X, Saito.Y, Suzuki.Y, Masuda.S, Tokuda.Y.

      Pleomorphic lobular carcinoma with lipid-producing activity: a report of 2 cases.

    • Suzuki.Y, Saeki.T, Aogi.K, Toi.M, Fujii.H, Inoue.K, Watanabe.T, Fujiwara.Y, Ito.Y, Takatsuka.Y, Iwata.H, Arioka.H, Tokuda.Y.

      A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.

    • Niikura.N, Kimura.M, Iwamoto.T, Hayashi.N, Shintoku.J, Saito.Y, Suzuki.Y, Tokuda.Y.

      Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.

    • Tsuda.B, Kametani.Y, Goto.Y, Saito.Y, Suzuki.Y, Habu.S, Inoko.H, Tokuda.Y.

      A human B cell receptor epitope-based erbB-2 peptide (N: 163-182) with pan-reactivity to the T cells of japanese breast cancer patients.

    • Niikura.N, Iwamoto.T, Masuda.S, Kumaki.N, Tang X, Shirane.M, Mori.K, Tsuda.B, Okamura.T, Saito.Y, Suzuki.Y, Tokuda.Y.

      Immunohistochemical Ki67 labeling index has a similar proliferation predictive power as various gene signatures breast cancer.

    • Mokuyasu.S, Suzuki.Y, Seto.T, Miyachi.H, Tokuda.Y.

      A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.

    • Saito.Y, Oshitanai.R, Terao.M, Terada.M, Tsuda.B, Okamura.T, Suzuki.Y, Tokuda.Y.

      Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.

    • Kumaki.M, Umemura.S, Tang.X, Saito.Y, Suzuki.Y, Tokuda.Y.

      Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.

    • Suzuki.Y, Saito.Y, Terao.M, Terada.M, Morioka.T, Tsuda.B, Okamura.T, Niikura.N, Tokuda.Y.

      Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.

    • Niikura.N, Kimura.M, Hirabayashi.K, Umemura.S, Minakawa.T, Shintoku.J, Suzuki.Y, Tokuda.Y.

      Breast conserving surgery for male noninvasive intracystic papillary carcinoma: a case report.

    • Saito.Y, Suzuki.Y, Tokuda.Y.

      Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.

    • Suzuki.Y, Tokuda.Y, Fujiwara.Y, Iwata.H, Sasaki.Y, Saji.S, Aogi.K, Nambu.Y, Suri A. Saeki.T, Takashima.S.

      Phase II study of gemcitabine monotherapy as salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.

    • Tokuda.Y, Suzuki.Y, Saito.Y, Umemura.S.

      The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.

    • Suzuki.Y, Tokuda.Y, Fujiwara.Y, Minami.H, Ohashi.Y, Saijo.N.

      Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.

    • Sato.H, Suzuki.Y, Fukasawa.M, Yasuda.M, Osamura.RY.

      De novo multiple endocrine neoplasia type 2B with noncardiogenic pulmonary edema as the presenting symptom.

    • Okada.K, Suzuki.Y, Saito.Y, Umemura.S, Tokuda.Y.

      Two cases of ductal adenoma of the breast.

    • Umemura.S, Takekoshi.S, Suzuki.Y, Saitoh.Y, Tokuda.Y, Osamura.RY.

      Estrogen receptor-negative and human epidermal growth factor receptor-2 negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.

    • Suzuki.Y, Tokuda.Y, Saito.Y, Umemura.S, Osamura.RY.

      Clinicopathological correlation between expression of PTHrP receptor and various prognostic factors in breast cancer without axillary lymph node metastasis.

    • Umemura.S, Itoh.J, Itoh.H, Serizawa.A, Saito.Y, Suzuki.Y, Tokuda.T, Tajima.T, Osamura.RY.

      Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?

    • Suzuki.Y, Tokuda.Y, Saito.Y, Ohta.M, Tajima.T.

      Combination of trastuzumab and vinorelbine in metastatic breast cancer.

    • Sekido.Y, Umemura.S, Takekoshi.S, Suzuki.Y, Tokuda.Y, Tajima.T, Osamura.RY.

      Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.

    • Umemura.S, Itoh.H, Ohta.M, Suzuki.Y, Kubota.M, Tokuda.Y, Tajima.T, Osamura.RY.

      Immunohistochemical evaluation of hormone receptor for routine practice of breast cancer: highly sensitive procedures significantly contribute to the correlation with biochemical assays.

    • Ohta.M, Tokuda.Y, Suzuki.Y, Kubota.M, Watanabe.T, Fujii.H, Sasaki.Y, Niwa.T, Makuuchi.H, Tajima.T.

      A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.

    • Tokuda.Y, Suzuki.Y, Ohta.M, Saito.Y, Kubota.M, Tajima.T, Umemura.S, Osamura.RY.

      Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan.

    • Tokuda.Y, Ohta.M, Suzuki.Y, Kubota.M, Tajima.T.

      Clinical development of trastuzumab in breast cancer.

    • Ohta.M, Tokuda.Y, Suzuki.Y, Kubota.M, Makuuchi.H, Tajima.T, Nasu.S, Suzuki.Y, Yasuda.S, Shohtsu.A.

      The whole-body PET for evaluation of bony metastases in the patients with breast cancer: comparison with Tc-99m MDP bone scintigraphy.

    • Suzuki.Y, Tokuda.Y, Okumura.A, Saito.Y, Ohta.M, Kubota.M, Makuuchi.H, Tajima.T, Umemura.S, Osamura.RY.

      Three cases of malignant lymphoma of the breast.

    • Ohta.M, Tokuda.Y, Saitoh.Y, Suzuki.Y, Okumura.A, Kubota.M, Makuuchi.H, Tajima.T, Yasuda.S, Shohtsu.A.

      Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer.

    • Okumura.A, Tokuda.Y, Ohta.M, Suzuki.Y, Saito.Y, Kuge.S, Makuuchi.H, Tajima.T, Nakamura.Y, Hotta.T.

      Autografting with peripheral blood CD34-positive cells following high-dose chemotherapy against breast cancer.

    • Ohta.M, Tokuda.Y, Kameya.T, Suzuki.Y, Kuge.S, Okumura.A, Kubota.M, Makuuchi.H, Tajima.T, Shimamura.K, Uchida.S, Mitsunaga.S, Tadokoro.K, Juji.T.

      GVHD after intraoperative blood transfusion: A rare and lethal condition.

    • Tajima.T, Kuge.S, Suzuki.Y, Okumura.A, Ohta.M, Tokuda.Y, Kubota.M.

      Dose-intensified chemotherapy for breast cancer: present and future prospects.

    • Yasuda.S, Shohtsu.A, Ide.M, Takagi.S, Suzuki.Y, Tajima.T.

      Diffuse F-18 FDG uptake in chronic thyroiditis.

    • Ohta.M, Tokuda.Y, Suzuki.Y, Kuge.S, Okumura.A, Kubota.M, Tajima.T, R. Osamura.RY, Mitomi.T.

      A case of multiple endocrine neoplasia type 2B.

    • 術前検査で乳癌を強く疑った線維腺腫の1例

      日本乳癌検診学会誌2012;21:78-81

    • 乳腺紡錐細胞癌の1例

      乳癌の臨床. 2008;23:135-139

    • 乳癌脳転移症例の臨床病理学的検討

      乳癌の臨床. 2004;19:606-607

    • 超音波検査にて乳腺浸潤が疑われた急性リンパ性白血病の1例.

      Journal of medical Ultrasonics 2000;27:805-810

    • 乳癌術後放射線照射後に発生したmalignant fibrous histiocytomaの1例

      日本臨床外科学会雑誌1996;57(12):2942-2946

    • 粘膜下腫瘍の形態を示し術前に確診が得られなかった高分化型早期胃癌の1例

      胃と腸. 1995;33(6):827-832

  • 所属病院関連情報Affiliated hospital Information

    乳房の悪性腫瘍
    ・治療実績手術あり:165件 在院日数:12.93日
    ・治療実績手術なし:14件 在院日数:データなし
    (平成30年度 DPCデータ)

  • 所属病院への転院情報Transfer information to your hospital

    TEL TEL:042-639-1111(代表)
    受付時間 受付時間:月~金曜日/第2・4・5週土曜日 8:00~11:00(休診日:日曜日、祝日、第1・3土曜日、 年末年始(12月29日~1月3日)、11月1日(東海大学建学記念日)
    URL URL:http://www.hachioji-hosp.tokai.ac.jp/raiin/gairai/jushin_annai/
Dr. 鈴木 育宏に治療相談を申し込む
お問い合わせフォーム